AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31550290 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestion indicating less painful stimuli (green or red colour) in unpredictable pain condition (UC)
Number of subjects: 56
Study 31550290 — intervention group
Group type: COMPARATOR
Intervention: No verbal suggestion (control group) in predictable pain condition (PC)
Number of subjects: 56
Study 31550290 — intervention group
Group type: COMPARATOR
Intervention: No verbal suggestion (control group) in unpredictable pain condition (UC)
Number of subjects: 56
Study 30132688 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal medial gastrocnemius recession and stretching
Number of subjects: 40
Study 30132688 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise program only
Number of subjects: 40
Study 27624603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (Group T)
Number of subjects: 57
Study 27624603 — intervention group
Group type: COMPARATOR
Intervention: Conventional loop diuretics (Group C)
Number of subjects: 57
Study 25373935 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing high sn-2 palmitate (sn-2; n=56)
Number of subjects: 165
Study 25373935 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing high sn-2 palmitate plus 3 g/L oligofructose (sn-2+OF; n=55)
Number of subjects: 165
Study 25373935 — intervention group
Group type: COMPARATOR
Intervention: Control formula (n=54)
Number of subjects: 165
Study 25373935 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk-fed group (HM; n=55)
Number of subjects: 165
Study 22932428 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. amphetamine dose of 0.3 mg/kg bodyweight
Number of subjects: 10
Study 22932428 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 19946868 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Cognition-Action (CA) intervention
Number of subjects: 49
Study 19946868 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care (C)
Number of subjects: 49
Study 18444166 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical perillyl alcohol (POH) cream (0.76% wt/wt) applied twice daily for 30 days
Number of subjects: 25
Study 18444166 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 30 days
Number of subjects: 25
Study 16418058 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based leisure-time physical activity motivational program
Number of subjects: 151
Study 16418058 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study 12907905 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (20 U; Botox)
Number of subjects: 50
Study 12907905 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 50
Study 10504600 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer learning module
Number of subjects: 58
Study 10504600 — intervention group
Group type: COMPARATOR
Intervention: Small-group seminar
Number of subjects: 58
Study 7795830 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss alone
Number of subjects: 100
Study 7795830 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Na intake alone
Number of subjects: 100
Study 7795830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight loss and reduced Na intake
Number of subjects: 100
Study 7795830 — intervention group
Group type: COMPARATOR
Intervention: Usual life-style (control group)
Number of subjects: 100
Study 2207867 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% polyacrylamide (Orcolon)
Number of subjects: 70
Study 2207867 — intervention group
Group type: COMPARATOR
Intervention: 1% sodium hyaluronate (Healon)
Number of subjects: 70
Study 359140 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment (low-level physical activity sessions, 14 of 18 sessions over 6 weeks)
Number of subjects: 651
Study 359140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 651
Study 31062722 — intervention group
Group type: EXPERIMENTAL
Intervention: One session of pulsed dye laser
Number of subjects: 22
Study 31062722 — intervention group
Group type: COMPARATOR
Intervention: Two sessions of pulsed dye laser (2 weeks apart)
Number of subjects: 22
Study 28341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU daily) and isokinetic training (3 times per week at 150°/s)
Number of subjects: 48
Study 28341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training (3 times per week at 150°/s)
Number of subjects: 48
Study 28341259 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 48
Study 28341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU daily) and isokinetic training
Number of subjects: 48
Study 28341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 48
Study 25629741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 222
Study 25629741 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 222
Study 23494035 — intervention group
Group type: EXPERIMENTAL
Intervention: TT clamp
Number of subjects: 1917
Study 23494035 — intervention group
Group type: COMPARATOR
Intervention: Standard bilamellar tarsal rotation (BLTR)
Number of subjects: 1917
Study 23494035 — intervention group
Group type: COMPARATOR
Intervention: Standard BLTR
Number of subjects: 1917
Study 22011820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine collagen calcium-alginate dressing covered with transparent polyurethane film (group A)
Number of subjects: 34
Study 22011820 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent polyurethane film dressing (group B)
Number of subjects: 34
Study 22011820 — intervention group
Group type: COMPARATOR
Intervention: Rayon soaked in 0.9% saline (group C)
Number of subjects: 34
Study 19457978 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy staff recording of treatment time
Number of subjects: 39
Study 19457978 — intervention group
Group type: COMPARATOR
Intervention: Video recording of treatment time
Number of subjects: 39
Study 19457978 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 39
Study 16710580 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment 4 times daily
Number of subjects: 40
Study 16710580 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% ointment 4 times daily
Number of subjects: 40
Study 15471389 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (250 mg on admission, then 125 mg/day)
Number of subjects: 78
Study 15471389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiomagnil (150 mg on admission, then 75 mg/day)
Number of subjects: 78
Study 15471389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 78
Study 15471389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clopidogrel (75 mg/day) and cardiomagnil (75 mg/day)
Number of subjects: 78
Study 15471389 — intervention group
Group type: COMPARATOR
Intervention: No dysaggregants
Number of subjects: 78
Study 11204665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (Eloxatin)
Number of subjects: 0
Study 11204665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with novel agents (e.g., thymidylate synthase inhibitors, epidermal growth factor‐receptor antagonists, microtubule interactive agents)
Number of subjects: 0
Study 9278830 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg intravenously (IV)
Number of subjects: 120
Study 9278830 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 25 mcg/kg i.v.
Number of subjects: 120
Study 9278830 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 8318783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of DDP at doses of 110 mg/m2
Number of subjects: 17
Study 8318783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of DDP at doses of 70 mg/m2
Number of subjects: 17
Study 8318783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of DDP with sodium thiosulfate (STS) rescue
Number of subjects: 17
Study 3519886 — intervention group
Group type: EXPERIMENTAL
Intervention: PC (cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 on day 1 every 28 days)
Number of subjects: 125
Study 3519886 — intervention group
Group type: COMPARATOR
Intervention: PAC (PC + doxorubicin 45 mg/m2)
Number of subjects: 125
Study 3519886 — intervention group
Group type: EXPERIMENTAL
Intervention: PC (in 75 patients submitted to second look)
Number of subjects: 125
Study 3519886 — intervention group
Group type: COMPARATOR
Intervention: PAC (in 75 patients submitted to second look)
Number of subjects: 125
Study 3519886 — intervention group
Group type: COMPARATOR
Intervention: PAC
Number of subjects: 125
Study 3519886 — intervention group
Group type: EXPERIMENTAL
Intervention: PC
Number of subjects: 125
Study 29631435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.7 mg at day 1 and month 5, with optional retreatment at month 10 or 11.
Number of subjects: 307
Study 29631435 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg at day 1 and monthly through month 5, with as-needed injections at month 6-11.
Number of subjects: 307
Study 29631435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 307
Study 29631435 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 307
Study 27406647 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA) with treated plasma ≥0.20 L/kg/day in the first 3 days after randomisation.
Number of subjects: 190
Study 27406647 — intervention group
Group type: COMPARATOR
Intervention: Current clinical practice (control group).
Number of subjects: 190
Study 25062396 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham Risk Profile (FRP) scores for patients with SHHD
Number of subjects: 149
Study 25062396 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham Risk Profile (FRP)
Number of subjects: 149
Study 22954564 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES) in Japanese patients
Number of subjects: 88
Study 22954564 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES) in US patients
Number of subjects: 88
Study 20111952 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic anatomic ACL reconstruction with hamstring tendons
Number of subjects: 0
Study 18799820 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg/d, n = 30)
Number of subjects: 90
Study 18799820 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (4 mg/d, n = 30)
Number of subjects: 90
Study 18799820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 90
Study 15767472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy treatment
Number of subjects: 254
Study 15767472 — intervention group
Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 254
Study 12217141 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth interventions
Number of subjects: 6
Study 10480471 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg/day ASA
Number of subjects: 17
Study 10480471 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg/day ASA
Number of subjects: 17
Study 10480471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8531541 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with Goretex bedcovers, benzyltannate spray, and a high‐filtration vacuum cleaner.
Number of subjects: 48
Study 8531541 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with cotton covers, water spray, and a conventional domestic vacuum cleaner.
Number of subjects: 48
Study 1830393 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin (PG) application
Number of subjects: 23
Study 1830393 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 23
Study 1830393 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride treatment
Number of subjects: 23
Study 6632131 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for nursing home staff
Number of subjects: 586
Study 6632131 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 586
Study 30700619 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion (PIBI) of 0.2% ropivacaine at 8 mL/h
Number of subjects: 34
Study 30700619 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) of 0.2% ropivacaine at 8 mL/h
Number of subjects: 34
Study 30700619 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion (PIBI) of 0.2% ropivacaine
Number of subjects: 34
Study 30700619 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) of 0.2% ropivacaine
Number of subjects: 34
Study 28728281 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes individuals
Number of subjects: 1719
Study 28728281 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, duration of diabetes, education, fasting blood glucose, ocular axial length
Number of subjects: 1719
Study 26084322 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic/virtually simulated activity (VR) group
Number of subjects: 21
Study 26084322 — intervention group
Group type: COMPARATOR
Intervention: Traditional, repetitive task practice (RTP) group
Number of subjects: 21
Study 26084322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 23886842 — intervention group
Group type: EXPERIMENTAL
Intervention: PFIT-s (Physical Function ICU Test - scored)
Number of subjects: 144
Study 21289455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring-injured group (HG)
Number of subjects: 30
Study 21289455 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 19784470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment
Number of subjects: 22
Study 19784470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15682244 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose cotrimoxazole (4 mg trimethoprim plus 20 mg sulfamethoxazole/kg)
Number of subjects: 1143
Study 15682244 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose cotrimoxazole (8 mg trimethoprim plus 40 mg sulfamethoxazole/kg)
Number of subjects: 1143
Study 12692782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) therapy
Number of subjects: 80
Study 12692782 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation (CAD) therapy
Number of subjects: 80
Study 10594485 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg TA orally
Number of subjects: 24
Study 10594485 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg glibenclamide orally
Number of subjects: 24
Study 10594485 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg TA+3.5 mg glibenclamide
Number of subjects: 24
Study 10594485 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg TA+50 mg acarbose
Number of subjects: 24
Study 10594485 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 24
Study 9569805 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 12
Study 9569805 — intervention group
Group type: EXPERIMENTAL
Intervention: Local metronidazole treatment
Number of subjects: 12
Study 9569805 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole treatment
Number of subjects: 12
Study 9569805 — intervention group
Group type: EXPERIMENTAL
Intervention: Local metronidazole combined with scaling and root planing
Number of subjects: 12
Study 9569805 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole combined with scaling and root planing
Number of subjects: 12
Study 9569805 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study 1812314 — intervention group
Group type: EXPERIMENTAL
Intervention: tannalbuminate (500 mg) and ethacridin‐lactate (50 mg), 1 tbl. b.i.d.
Number of subjects: 77
Study 1812314 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 77
Study 1812314 — intervention group
Group type: EXPERIMENTAL
Intervention: tannalbuminate and ethacridin‐lactate
Number of subjects: 77
Study 6871776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic protamine (3 mg . Kg‐1 injected over 30 sec)
Number of subjects: 10
Study 6871776 — intervention group
Group type: COMPARATOR
Intervention: Intravenous protamine (3 mg . Kg‐1 injected over 30 sec)
Number of subjects: 10
Study 30540966 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition (oral supplementation enriched with arginine, ω‐3 fatty acids, and dietary nucleotides)
Number of subjects: 60
Study 30540966 — intervention group
Group type: COMPARATOR
Intervention: Preoperative immunonutrition (same enriched formula before surgery and standard enteral nutrition following surgery)
Number of subjects: 60
Study 30540966 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition
Number of subjects: 60
Study 30540966 — intervention group
Group type: COMPARATOR
Intervention: Preoperative immunonutrition
Number of subjects: 60
Study 28885466 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Deficits Questionnaire (PDQ)
Number of subjects: 183
Study 26218009 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation before clinical experience
Number of subjects: 0
Study 26218009 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation after clinical experience
Number of subjects: 0
Study 26218009 — intervention group
Group type: COMPARATOR
Intervention: Clinical experience
Number of subjects: 0
Study 26218009 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation (timing not specified)
Number of subjects: 0
Study 24052490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 h) applied daily for 3 days
Number of subjects: 17
Study 21909730 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D(3) 6,500 IU/day (20,000 IU twice per week + 800 IU/day)
Number of subjects: 297
Study 21909730 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose vitamin D(3) 800 IU/day (placebo twice per week + 800 IU/day)
Number of subjects: 297
Study 19650844 — intervention group
Group type: EXPERIMENTAL
Intervention: dobutamine (2.5 microg x kg(‐1) x min(‐1))
Number of subjects: 11
Study 19650844 — intervention group
Group type: EXPERIMENTAL
Intervention: dopexamine (1 microg x kg(‐1) x min(‐1))
Number of subjects: 11
Study 17956827 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily LPV/r, tenofovir (TDF), and lamivudine (3TC)
Number of subjects: 72
Study 17956827 — intervention group
Group type: COMPARATOR
Intervention: Control arm (existing regimen)
Number of subjects: 72
Study 15885349 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20mg/day)
Number of subjects: 14
Study 15885349 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha treatment without pre-emptive antidepressant therapy
Number of subjects: 14
Study 12360839 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program consisting of twenty 2-hr group sessions over 1 year
Number of subjects: 0
Study 12360839 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9793810 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg i.v.
Number of subjects: 60
Study 9793810 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1 mg/kg i.v.
Number of subjects: 60
Study 9793810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) i.v.
Number of subjects: 60
Study 8520195 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 12
Study 8520195 — intervention group
Group type: COMPARATOR
Intervention: SUZI
Number of subjects: 12
Study 11527130 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 21
Study 11527130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 21
Study 11527130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bisoprolol and Nifedipine
Number of subjects: 21
Study 11527130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 370526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 370526 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl testosterone
Number of subjects: 0
Study 370526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31300029 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred intensity exercise (3 sessions/week for 4 weeks)
Number of subjects: 38
Study 31300029 — intervention group
Group type: COMPARATOR
Intervention: Prescribed intensity exercise (3 sessions/week for 4 weeks)
Number of subjects: 38
Study 28806095 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections at 7 and 14 days post-surgery
Number of subjects: 60
Study 28806095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP injections)
Number of subjects: 60
Study 28806095 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 60
Study 26138715 — intervention group
Group type: EXPERIMENTAL
Intervention: SocialVille training program
Number of subjects: 128
Study 26138715 — intervention group
Group type: COMPARATOR
Intervention: Active control computer game condition
Number of subjects: 128
Study 23782553 — intervention group
Group type: EXPERIMENTAL
Intervention: predictD‐CCRT intervention (personalized intervention by family physicians)
Number of subjects: 3286
Study 23782553 — intervention group
Group type: COMPARATOR
Intervention: usual care (control group)
Number of subjects: 3286
Study 23782553 — intervention group
Group type: EXPERIMENTAL
Intervention: predictD‐CCRT intervention
Number of subjects: 3286
Study 22282958 — intervention group
Group type: EXPERIMENTAL
Intervention: IBN/SNAC formulation co-administered with metformin
Number of subjects: 22
Study 22282958 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 22